[article] 
inJournal of Child Psychology and Psychiatry > 62-6 (June 2021) . - p.701-703

Titre :	Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020)
Type de document :	Texte imprimé et/ou numérique
Auteurs :	L. C. FARHAT, Auteur ; Michael H. BLOCH, Auteur
Article en page(s) :	p.701-703
Langues :	Anglais (eng)
Mots-clés :	Atomoxetine Hydrochloride/pharmacology  Attention Deficit Disorder with Hyperactivity/drug therapy  Autism Spectrum Disorder/drug therapy  Child  Guanfacine/pharmacology  Humans  Methylphenidate/pharmacology
Index. décimale :	PER Périodiques
Résumé :	In this issue, Rodrigues et al. (2020) present a systematic review with meta-analyses that reports the efficacy of five treatments for children with attention-deficit hyperactivity disorder symptoms in the context of autism spectrum disorder - (a) methylphenidate; (b) atomoxetine; (c) guanfacine; (d) aripiprazole; and (e) risperidone. In this commentary, we highlight the contrast between the scarce evidence base of treatment for ADHD in the context of autism and other subpopulations, such as tic disorders and intellectual disability, and the extensive evidence base of treatment for ADHD in general. The commentary weighs about the conundrum clinicians face of whether to rely on the limited evidence base of treatment for ADHD in subpopulation, or to derive conclusions from the larger body of evidence of treatment for ADHD in general. The commentary also discusses potential avenues for future research to address this clinical problem.
En ligne :	http://dx.doi.org/10.1111/jcpp.13374
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455

[article] Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020) [Texte imprimé et/ou numérique] / L. C. FARHAT, Auteur ; Michael H. BLOCH, Auteur . - p.701-703.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 62-6 (June 2021) . - p.701-703

Mots-clés :	Atomoxetine Hydrochloride/pharmacology  Attention Deficit Disorder with Hyperactivity/drug therapy  Autism Spectrum Disorder/drug therapy  Child  Guanfacine/pharmacology  Humans  Methylphenidate/pharmacology
Index. décimale :	PER Périodiques
Résumé :	In this issue, Rodrigues et al. (2020) present a systematic review with meta-analyses that reports the efficacy of five treatments for children with attention-deficit hyperactivity disorder symptoms in the context of autism spectrum disorder - (a) methylphenidate; (b) atomoxetine; (c) guanfacine; (d) aripiprazole; and (e) risperidone. In this commentary, we highlight the contrast between the scarce evidence base of treatment for ADHD in the context of autism and other subpopulations, such as tic disorders and intellectual disability, and the extensive evidence base of treatment for ADHD in general. The commentary weighs about the conundrum clinicians face of whether to rely on the limited evidence base of treatment for ADHD in subpopulation, or to derive conclusions from the larger body of evidence of treatment for ADHD in general. The commentary also discusses potential avenues for future research to address this clinical problem.
En ligne :	http://dx.doi.org/10.1111/jcpp.13374
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455